A Spotlight on Innovations and Considerations

Innovation is one of the strongest core values at MJH Life Sciences, and spotlighting advances in dermatologic care remains a top priority for the Dermatology Times^® team. In this month’s issue, we take an in-depth look at the 1-year anniversary of the approval of deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with moderate to severe plaque psoriasis. A panel of clinicians delves into the drug’s efficacy, its pros and cons, what makes it different from other psoriasis therapies, and special considerations for patients with skin of color. We are also thrilled to share a psoriasis supplement focusing on psoriasis treatment, advances, and clinical resources to best serve individuals with skin of color and other underserved populations.

Gorodenkoff/AdobeStock

On the heels of Labor Day weekend, we discuss how skin cancer can have a lasting impact on workers in certain career fields or those with heroic roles in historic events. Discover how aircrews are more susceptible to skin cancers and how dermatologic care amid their busy schedules is critical. There is also a look at areas of the body on which rescue workers from the September 11, 2001, attacks showed a higher risk of melanoma years later. These are also insightful considerations for treating patients who are firefighters.

This is an issue packed with the latest research, monthly columns to strengthen your practice management, and considerations on a variety of topics to help dermatologists, nurse practitioners, physician assistants, and aspiring clinicians enhance their professional experiences.

Do not miss a moment of new data, pearls, interviews, videos, and podcasts with leaders in the field. Subscribe to Dermatology Times e-newsletters, follow us on social media, and email us at DTEditor@mmhgroup.com to share your insights.